Furmonertinib is an oral, brain-penetrating EGFR tyrosine kinase inhibitor (TKI) with a broad spectrum of activity and selectivity for mutations, including EGFR 20ins mutations in NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.